Inhibition of midkine along with an NF-κB inhibitor targeting HCC cells (such as CTCs in different stages over the course of disease progression) may represent a novel combinatorial strategy to improve the therapeutic outcome of HCC. Here, NFKB1 is linked to hepatocellular carcinoma.